ACCD News and Press, Accolade Inc. From 11/27/23

SEATTLE, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Piper Sandler 35 th Annual Healthcare Conference in New York on Wednesday, November 29, 2023 at 10:00 am ET. ...

2023-11-19 08:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-16 16:08:42 ET More on Accolade Accolade: Multiples Should Rerate As ACCD Continues To Execute Obesity drug coverage among U.S. employers to nearly double in 2024: survey Accolade FQ2 2024 Earnings Preview For further details see: Accolade announc...

SEATTLE, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it has entered into separate, privately negotiated transactions with certain holders of its outstanding 0.50% Convertible Senior Notes due 2026 (the “Notes”) to repurchase (the “Repu...

SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves millions of members, today announced that it will be presenting at the Stephen Annual Investment Conference in Nashville on Wednesday, November 15, 2023 at 11:00am CT. A webcast of the...

Accolade Named to 2023 Deloitte Technology Fast 500™ PR Newswire Attributes 227% revenue growth to a relentless focus on delivering exceptional outcomes SEATTLE , Nov. 8, 2023 /PRNewswire/ -- Accolade today announced it has been named to the Delo...

2023-10-19 10:29:42 ET Summary ACCD reported strong 2Q24 results, beating consensus estimates for revenue and adjusted EBITDA. Management's positive outlook on the demand environment and growing health plan channel support ACCD's growth prospects. Despite a contraction in mult...

2023-10-10 14:03:56 ET More on Lilly, Novo, etc. Eli Lilly: Do Not Chase This Stock Over The Cliff Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase Eli Lilly POINTs Toward Radiopharmaceutical Ambitions Novo Nordisk lawsuit over compounded weight...

GLP-1 Coverage in Employer Plans Could Nearly Double in 2024 PR Newswire Employer survey: 25% of employers currently offer coverage and most experience positive outcomes; 4 in 10 consider it an immediate concern and intend to offer in 2024; while 21% of HR decision-makers are ...

2023-10-06 11:31:49 ET Shares of Accolade (NASDAQ: ACCD) were down more than 25% for the week as of 10 a.m. on Friday, according to data provided by S&P Global Market Intelligence . The healthcare benefits company's stock closed last week at $10.58 a share then fell to a...